1. Treatment appropriateness of direct oral anticoagulants in patients with atrial fibrillation for stroke prevention: A real-world prospective study.
- Author
-
Pasebani Y, Rafati A, Dalouchi S, Bahadori MJ, Ghoshouni H, Haghjoo M, Fazelifar AF, Alizadeh-Diz A, Madadi S, Kamali F, Hadavand N, Talasaz AH, Lip GYH, Emkanjoo Z, and Sadeghipour P
- Subjects
- Humans, Male, Female, Aged, Prospective Studies, Administration, Oral, Aged, 80 and over, Middle Aged, Inappropriate Prescribing statistics & numerical data, Inappropriate Prescribing prevention & control, Factor Xa Inhibitors therapeutic use, Factor Xa Inhibitors administration & dosage, Atrial Fibrillation drug therapy, Atrial Fibrillation complications, Rivaroxaban therapeutic use, Rivaroxaban administration & dosage, Stroke prevention & control, Pyrazoles therapeutic use, Pyrazoles administration & dosage, Pyridones therapeutic use, Pyridones administration & dosage, Anticoagulants therapeutic use, Anticoagulants administration & dosage
- Abstract
Introduction: Inappropriate use of direct oral anticoagulants (DOACs) is common, affecting up to 30% of atrial fibrillation (AF) population receiving treatment for stroke prevention. This study assessed appropriateness of anticoagulation in anticoagulation-naive AF patients treated with DOACs during a 12-month prospective follow-up., Methods: This prospective cohort study included all anticoagulation-naive AF patients referred for anticoagulation for stroke prevention at a tertiary cardiovascular center. Participants were prospectively followed through phone call interviews by a dedicated nurse at 1, 3, 6, 9, and 12 months after enrollment., Results: Of 403 anticoagulation-naive AF patients, rivaroxaban was prescribed for 325 patients (80.7%) and apixaban for 78 (19.3%). Inappropriate therapy was observed in 23% (76/325) and 46% (36/78) of patients treated with rivaroxaban and apixaban, respectively. Undertreatment was predominant scenario for both drugs, detected in 78.5% (78/112) of patients treated inappropriately, and was more frequently observed with apixaban versus rivaroxaban (44.8% vs 16.3%). During 12 months, inappropriate treatment was corrected in only 13% of all patients. The multivariate regression model identified creatinine clearance ≤ 49 mL/min (odds ratio [OR], 2.17; 95% confidence interval [CI], 1.12 to 4.21), female sex (OR, 1.81; 95% CI, 1.11 to 2.97), and age ≥ 80 years (OR, 1.85; 95% CI, 1.22 to 2.83) as independent covariates associated with inappropriate dosing., Conclusions: Inappropriate therapy with DOACs for stroke prevention in patients with AF is common, and the dosage were corrected in few patients during the 12-month follow-up. Our findings highlight the persistent lack of knowledge regarding appropriate DOAC dosage and need for continuous education., Competing Interests: Declarations. Competing interests: Dr. Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multi morbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation program me under grant agreement No 899871., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF